Cargando…

Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK

OBJECTIVES: To assess consistency in the format and content, and overlap of subject and timing, of medication safety letters issued by regulatory health authorities to healthcare providers in Canada, the USA and the UK. DESIGN: A cross-sectional study comparing medication safety letters issued for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjerre, Lise M, Parlow, Simon, de Launay, David, Hogel, Matthew, Black, Cody D, Mattison, Donald R, Grimshaw, Jeremy M, Watson, Margaret C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194396/
https://www.ncbi.nlm.nih.gov/pubmed/30297342
http://dx.doi.org/10.1136/bmjopen-2017-020150
_version_ 1783364221698834432
author Bjerre, Lise M
Parlow, Simon
de Launay, David
Hogel, Matthew
Black, Cody D
Mattison, Donald R
Grimshaw, Jeremy M
Watson, Margaret C
author_facet Bjerre, Lise M
Parlow, Simon
de Launay, David
Hogel, Matthew
Black, Cody D
Mattison, Donald R
Grimshaw, Jeremy M
Watson, Margaret C
author_sort Bjerre, Lise M
collection PubMed
description OBJECTIVES: To assess consistency in the format and content, and overlap of subject and timing, of medication safety letters issued by regulatory health authorities to healthcare providers in Canada, the USA and the UK. DESIGN: A cross-sectional study comparing medication safety letters issued for the purpose of alerting healthcare providers to newly identified medication problems associated with medications already on the market. SETTING: Online databases operated by Health Canada, the US Food and Drug Administration and the UK Medicines and Healthcare products Regulatory Agency were searched to select medication safety letters issued between 1 January 2010 and 31 December 2014. Format, content and timing of each medication safety letter were assessed using an abstraction tool comprising 21 characteristics deemed relevant by consensus of the research team. MAIN OUTCOME MEASURES: Main outcome measures included, first, characteristics (format and content) of medication safety letters and second, overlap of subject and release date across countries. RESULTS: Of 330 medication safety letters identified, 227 dealt with unique issues relating to medications available in all three countries. Of these 227 letters, 21 (9%) medication problems were the subject of letters released in all three countries; 40 (18%) in two countries and 166 (73%) in only one country. Only 13 (62%) of the 21 letters issued in all three countries were released within 6 months of each other. CONCLUSIONS: Significant discrepancies in both the subject and timing of medication safety letters issued by health authorities in three countries (Canada, the USA and the UK) where medical practice is otherwise comparable, raising questions about why, how and when medication problems are identified and communicated to healthcare providers by the authorities. More rapid communication of medication problems and better alignment between authorities could enhance patient safety.
format Online
Article
Text
id pubmed-6194396
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-61943962018-10-24 Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK Bjerre, Lise M Parlow, Simon de Launay, David Hogel, Matthew Black, Cody D Mattison, Donald R Grimshaw, Jeremy M Watson, Margaret C BMJ Open Pharmacology and Therapeutics OBJECTIVES: To assess consistency in the format and content, and overlap of subject and timing, of medication safety letters issued by regulatory health authorities to healthcare providers in Canada, the USA and the UK. DESIGN: A cross-sectional study comparing medication safety letters issued for the purpose of alerting healthcare providers to newly identified medication problems associated with medications already on the market. SETTING: Online databases operated by Health Canada, the US Food and Drug Administration and the UK Medicines and Healthcare products Regulatory Agency were searched to select medication safety letters issued between 1 January 2010 and 31 December 2014. Format, content and timing of each medication safety letter were assessed using an abstraction tool comprising 21 characteristics deemed relevant by consensus of the research team. MAIN OUTCOME MEASURES: Main outcome measures included, first, characteristics (format and content) of medication safety letters and second, overlap of subject and release date across countries. RESULTS: Of 330 medication safety letters identified, 227 dealt with unique issues relating to medications available in all three countries. Of these 227 letters, 21 (9%) medication problems were the subject of letters released in all three countries; 40 (18%) in two countries and 166 (73%) in only one country. Only 13 (62%) of the 21 letters issued in all three countries were released within 6 months of each other. CONCLUSIONS: Significant discrepancies in both the subject and timing of medication safety letters issued by health authorities in three countries (Canada, the USA and the UK) where medical practice is otherwise comparable, raising questions about why, how and when medication problems are identified and communicated to healthcare providers by the authorities. More rapid communication of medication problems and better alignment between authorities could enhance patient safety. BMJ Publishing Group 2018-10-08 /pmc/articles/PMC6194396/ /pubmed/30297342 http://dx.doi.org/10.1136/bmjopen-2017-020150 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Pharmacology and Therapeutics
Bjerre, Lise M
Parlow, Simon
de Launay, David
Hogel, Matthew
Black, Cody D
Mattison, Donald R
Grimshaw, Jeremy M
Watson, Margaret C
Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK
title Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK
title_full Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK
title_fullStr Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK
title_full_unstemmed Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK
title_short Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK
title_sort comparative, cross-sectional study of the format, content and timing of medication safety letters issued in canada, the usa and the uk
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194396/
https://www.ncbi.nlm.nih.gov/pubmed/30297342
http://dx.doi.org/10.1136/bmjopen-2017-020150
work_keys_str_mv AT bjerrelisem comparativecrosssectionalstudyoftheformatcontentandtimingofmedicationsafetylettersissuedincanadatheusaandtheuk
AT parlowsimon comparativecrosssectionalstudyoftheformatcontentandtimingofmedicationsafetylettersissuedincanadatheusaandtheuk
AT delaunaydavid comparativecrosssectionalstudyoftheformatcontentandtimingofmedicationsafetylettersissuedincanadatheusaandtheuk
AT hogelmatthew comparativecrosssectionalstudyoftheformatcontentandtimingofmedicationsafetylettersissuedincanadatheusaandtheuk
AT blackcodyd comparativecrosssectionalstudyoftheformatcontentandtimingofmedicationsafetylettersissuedincanadatheusaandtheuk
AT mattisondonaldr comparativecrosssectionalstudyoftheformatcontentandtimingofmedicationsafetylettersissuedincanadatheusaandtheuk
AT grimshawjeremym comparativecrosssectionalstudyoftheformatcontentandtimingofmedicationsafetylettersissuedincanadatheusaandtheuk
AT watsonmargaretc comparativecrosssectionalstudyoftheformatcontentandtimingofmedicationsafetylettersissuedincanadatheusaandtheuk